## **GUIDELINES (JSH 2014)**

## List of Abbreviations and Acronyms

Hypertension Research (2014) 37, 388-390; doi:10.1038/hr.2014.19

## Study names

Study names		EUROPA	European trial on reduction of cardiac events with
AASK	African American study of kidney disease and		perindopril in stable coronary artery disease
	hypertension	EWPHE	European working party on high blood pressure
ABCD	appropriate blood pressure control in diabetes		in the elderly trial
ACCESS	acute candesartan cilexetil evaluation in stroke	EXCEED	Exforge intensive control of hypertension to
	survivors		evaluate efficacy in diastolic dysfunction
ACCOMPLISH	avoiding cardiovascular events through combi-	FACET	fosinopril vs. amlodipine cardiovascular events
	nation therapy in patients living with systolic		randomized trial
	hypertension	FEVER	felodipine event reduction
ACCORD	action to control cardiovascular risk in diabetes	GUARD	gauging albuminuria reduction with Lotrel in
ACCORD BP	action to control cardiovascular risk in diabetes		diabetic patients with hypertension
	blood pressure	HEP	hypertension in elderly patients
ACTION	a coronary disease trial investigating outcome	HIJ-CREATE	Heart institute of Japan candesartan randomized
	with nifedipine		trial for evaluation in coronary artery disease
ADVANCE	action in diabetes and vascular disease: preterax	HOMED BP	hypertension objective treatment based on
	and diamicron MR-controlled evaluation	UOT	measurement by electrical devices of blood pressure
ALLHAT	antihypertensive and lipid-lowering treatment to	HOT	hypertension optimal treatment
	prevent heart attack trial	HYVET	hypertension in the very elderly trial
ALTITUDE	aliskiren trial in type 2 diabetes using cardiorenal	IDHOCO	international database of home blood pressure in
ANDD 2	endpoints	IDNE	relation to cardiovascular outcome
ANBP-2	second Australian national blood pressure study atherosclerosis risk in communities	IDNT	irbesartan diabetic nephropathy trial
ARIC		INNOVATION	incipient to overt: angiotensin II receptor blocker,
ASCOT DDI A	Anglo-Scandinavian cardiac outcome trial		telmisartan, investigation on type 2 diabetic
ASCOT-BPLA	Anglo-Scandinavian cardiac outcomes trial—	INSIGHT	nephropathy
ASCOT LLA	blood-pressure-lowering arm	INSIGHT	international Nifedipine GITS study: intervention
ASCOT-LLA	Anglo-Scandinavian cardiac outcomes trial—	INFTED ACT	as a goal in hypertension treatment
BAT	lipid-lowering arm bleeding with antithrombotic therapy	INTERACT	intensive blood pressure reduction in acute cere- bral hemorrhage trial
CAMELOT	comparison of amlodipine vs. enalapril to limit	INTERMAP	international study of macro- and micronutrients
CAMILLOI	occurrences of thrombosis	INTERNAF	and blood pressure
CAPPP	captopril prevention project	INTERSALT	international study of salt and blood pressure
CASE-J	candesartan antihypertensive survival evaluation	INVEST	international verapamil-trandolapril study
,	in Japan	IRMA-2	irbesartan in patients with type 2 diabetes and
Challenge-DM	candesartan antihypertensive assessment for long		microalbuminuria study
0	life enrolled by general practitioners-target on	J-HOME	Japan home vs. office blood pressure measure-
	hypertension with DM	·	ment evaluation
CHS	cardiovascular health study	J-LIT	Japan lipid intervention trial
CIRCS	circulatory risk in communities study	J-MIND	Japan multicenter investigation of antihyperten-
CONVINCE	controlled onset verapamil investigation of		sive treatment for nephropathy in diabetes study
	cardiovascular end points	JATOS	Japanese trial to assess optimal systolic blood
COPE	combination therapy of hypertension to prevent		pressure in elderly hypertensive patients
	cardiovascular events	JMIC-B	Japan multicenter investigation for cardiovascular
CREDO-Kyoto	coronary revascularization demonstrating		disease-B
·	outcome study in Kyoto	ЈРНС	Japan public health center-based prospective
DASH	dietary approaches to stop hypertension		study
EPOCH-JAPAN	evidence for cardiovascular prevention from	LIFE	losartan intervention for endpoint reduction in
	observational cohorts in Japan		hypertension

		1	
MARVAL	microalbuminuria reduction with valsartan	ba PWV	brachial-ankle PWV
MEGA	management of elevated cholesterol in the	BDI	Beck depression inventory
	primary prevention group of adult Japanese	BMI	body mass index
MOSES	morbidity and mortality after stroke, eprosartan	BP	blood pressure
	compared with nitrendipine for secondary	BTZ	benzothiazepine
	prevention	CAD	coronary artery disease
MRC II	medical research council study	CAVI	cardio-ankle vascular index
NHANES	national health and nutrition examination survey	CCr	creatinine clearance
NICS-EH	national intervention cooperative study in elderly	cf PWV	carotid-femoral pulse wave velocity
	hypertensives	CKD	chronic kidney disease
NIPPON DATA	national integrated project for prospective obser-	COPD	chronic obstructive pulmonary disease
	vation of non-communicable disease and its	COX	cyclooxygenase
	trends in the aged	CPAP	continuous positive airway pressure
NORMALISE	Norvasc for regression of manifest atherosclerotic	CRP	C-reactive protein
	lesions by intravascular sonographic evaluation	СТ	computed tomography
OmniHeart	optimal macronutrient intake trial to prevent	CTA	computed tomography angiography
	heart disease	CTR	cardio-thoracic ratio
ONTARGET	ongoing telmisartan alone and in combination	CVD	cardiovascular disease
	with ramipril global endpoint trial	CYP	cytochrome P450
OSCAR	olmesartan and calcium antagonists randomized	DBP	diastolic blood pressure
	study	DHA	docosahexaenoic acid
PATE-	practitioner's trial on the efficacy of antihyper-	DHP	dihydropyridine
Hypertension	tensive treatment in the elderly hypertension	DRI	direct renin inhibitor
PET	positron emission tomography	DSWMH	deep and subcortical white matter hyperintensity
PRoFESS	prevention regimen for effectively avoiding	eGFR	estimated glomerular filtration rate
1101200	second strokes	EPA	eicosapentaenoic acid
PROGRESS	perindopril protection against recurrent stroke	ESRD	end-stage renal disease
1 RO GRESS	study	FMD	flow-mediated dilatation
REIN	ramipril efficacy in nephropathy	GDS	geriatric depression scale
RENAAL	reduction of end points in NIDDM with the	GWAS	genome-wide association study
<b>REIW</b> <i>M</i> <b>E</b>	angiotensin II antagonist losartan	HDL	high-density lipoprotein
ROADMAP	randomized olmesartan and diabetes micro-	HELLP	hemolysis/elevated liver enzymes/low platelet
KOADIVIAI	albuminuria prevention	TILLLI	count
SAMURAI-ICH	stroke acute management with urgent risk-factor	HMC CoA	
SAMUKAI-ICH	assessment and improvement-ICH	HMG-CoA ICER	hydroxymethylglutaryl-CoA incremental cost-effectiveness ratio
SC AST	Scandinavian candesartan acute stroke trial		
SCAST		ISA	intrinsic sympathomimetic activity
SHEP	systolic hypertension in the elderly program Shanghai trial of nifedipine in the elderly	LDL	low-density lipoprotein
STONE		LVH	left ventricular hypertrophy
STOP-	Swedish trial in old patients with hypertension	MCI	mild cognitive impairment
Hypertension		MDCT	multi-detector computed tomography
Syst-China	systolic hypertension in China	MDRD	modification of diet in renal disease
Syst-Eur	systolic hypertension in Europe	MetS	metabolic syndrome
TONE	trial of nonpharmacologic interventions in the	MMSE	mini-mental state examination
LIUDD 0	elderly	MRA	magnetic resonance angiography
UKPDS	UK prospective diabetes study	MRI	magnetic resonance imaging
VALISH	valsartan in elderly isolated systolic hypertension	NSAIDs	non-steroidal anti-inflammatory drugs
VALUE	valsartan antihypertensive long-term use evalua-	NT-proBNP	N-terminal prohormone of brain natriuretic
	tion	0.000	peptide
WASID	warfarin-aspirin symptomatic intracranial disease	OGTT	oral glucose tolerance test
		OSAS	obstructive sleep apnea syndrome
Technical terms		PA	primary aldosteronism
ABI	ankle brachia index	PAC	plasma aldosterone concentration
ABPM	ambulatory blood pressure monitoring	PIGF	placental growth factor
ACE	angiotensin-converting enzyme	PN	periarteritis nodosa
ACTH	adrenocorticotropic hormone	PPARγ	peroxisome proliferator-activated receptor
ADL	activities of daily living		gamma
AHI	apnea–hypopnea index	PRA	plasma renin activity
AI	augmentation index	PSG	polysomnography
ARB	angiotensin ii receptor blocker	PSS	progressive systemic sclerosis
ARC	active renin concentration	PSV	peak systolic velocity
ARR	aldosterone-to-renin ratio	PTRA	percutaneous transluminal renal angioplasty
			~

Abbreviation/Acronym

DITT		700	
PVH	periventricular hyperintensity	ESC	European society of cardiology
PWV	pulse wave velocity	ESH	European society of hypertension
QALY	quality-adjusted life year	FDA	US food and drug administration
QOL	quality of life	IOM	institute of medicine
RCT	randomized controlled trial	ISH	international society of hypertension
RVHT	renovascular hypertension	JNC	joint national committee on prevention, detec-
SBP	systolic blood pressure		tion, evaluation, and treatment of high blood
SFlt	soluble fms-like tyrosine kinase		pressure
t-PA	tissue plasminogen activator	JSH	Japanese society of hypertension
TIA	transient ischemic attack	KDIGO	kidney disease improving global outcomes
TRAb	thyroid receptor antibodies	Minds	medical information network distribution service
TSAb	thyroid-stimulating antibody	MRC	medical research council
TSH	thyroid-stimulating hormone	NCEP-ATP III	third report of the national cholesterol education
URAT 1	urate transporter 1		program (NCEP) expert panel on detection, evaluation and treatment of high blood choles-
Organizations			terol in adults (adult treatment panel III)
ACSM	American college of sports medicine	NGSP	national glycohemoglobin standardization
ADA	American diabetes association		program
AHA	American heart association	NICE	national institute for health and care excellence
BHS	British hypertension society	WHO	world health organization

npg 390